Navigation Links
Galectin Therapeutics Reports Full Year and Fourth Quarter 2012 Financial Results
Date:3/29/2013

k related to the PROCAPS agreement which we terminated in 2012 and decreased litigation costs related to a settlement in 2011.

About Galectin TherapeuticsGalectin Therapeutics (NASDAQ: GALT) is developing promising carbohydrate-based therapies for the treatment of fibrotic liver disease and cancer based on the Company's unique understanding of galectin proteins, key mediators of biologic function.  We are leveraging extensive scientific and development expertise as well as established relationships with external sources to achieve cost effective and efficient development.  We are pursuing a clear development pathway to clinical enhancement and commercialization for our lead compounds in liver fibrosis and cancer.  Additional information is available at www.galectintherapeutics.com.

Forward Looking StatementsThis press release contains, in addition to historical information, forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.  These statements relate to future events or future financial performance, and use words such as "may," "estimate," "could," "expect" and others.  They are based on our current expectations and are subject to factors and uncertainties which could cause actual results to differ materially from those described in the statements.  Factors that could cause our actual performance to differ materially from those discussed in the forward-looking statements include, among others: incurrence of operating losses since our inception, uncertainty as to adequate financing of our operations, extensive and costly regulatory oversight that could restrict or prevent product commercialization, inability to achieve commercial product acceptance, inability to protect our intellectual property, dependence on strategic partnerships, product c
'/>"/>

SOURCE Galectin Therapeutics Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Galectin-3 Assessed as a Biomarker of Heart Failure: Key Clinical Trial Findings Published by Dove Medical Press
2. Cell Therapeutics, Inc. Reports Results of Annual Meeting of Shareholders
3. Nile Therapeutics Reports 2011 Third Quarter Financial Results
4. Nile Therapeutics Announces Top-Line Results in Clinical Trial Evaluating the Subcutaneous Infusion of Cenderitide, Meets Primary Endpoint
5. Fate Therapeutics Strengthens Its iPSC Platform
6. Amsterdam Molecular Therapeutics Provides Business Update for the Third Quarter 2011
7. MarketsandMarkets: Global Prostate Cancer Therapeutics Market worth $6,457 Million by 2020
8. MarketsandMarkets: Leukemia Therapeutics Market Worth $11.3 Billion by 2020
9. Roche Signs Agreement with PTC Therapeutics to Advance Treatment for Spinal Muscular Atrophy (SMA)
10. Echo Therapeutics Announces Positive Results of Clinical Trial of its Symphony® Transdermal Continuous Glucose Monitoring (tCGM) System in Patients With Type 1 and Type 2 Diabetes
11. Aratana Therapeutics Completes $15 Million Series B Financing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... MENLO PARK, Calif. , Aug. 28, 2014 ... company focused on developing novel mid- to late-stage ... raised $7.0 million in its first round of ... AshHill Biomedical Investments and Hercules Bioventures with participation ... biotech entrepreneur and pharmaceutical executive, Dr. Larry ...
(Date:8/28/2014)... 2014 Earlier this month, a ... partnership with the U.S. Air Force on the performance ... indicated that this type of fuel made from mustard ... be important to America’s Eco friendly future. In fact, ... mandate to become independent of foreign oil over the ...
(Date:8/27/2014)... Utah (PRWEB) August 27, 2014 Varian ... will expand its current Salt Lake City manufacturing facility ... outside of Utah to ultimately create 1,000 new full ... years. , “Utah is home to hardworking people ... can be credited with Varian’s success in the manufacturing ...
(Date:8/27/2014)... Aug. 27, 2014 Reportlinker.com announces ... available in its catalogue: Global ... http://www.reportlinker.com/p02316661/Global-Biodegradable-Packaging-Materials-Market-2014-2018.html About ... that are readily decomposed by the action ... non-degradable packaging in terms of raw materials, ...
Breaking Biology Technology:Armetheon Completes $7.0 Million Series A Financing 2Armetheon Completes $7.0 Million Series A Financing 3Can Small Farmers and a New Seed Based Biofuel “Green” the World? Major Universities and Even the U.S. Air Force Seem to Think So 2Can Small Farmers and a New Seed Based Biofuel “Green” the World? Major Universities and Even the U.S. Air Force Seem to Think So 3Can Small Farmers and a New Seed Based Biofuel “Green” the World? Major Universities and Even the U.S. Air Force Seem to Think So 4Can Small Farmers and a New Seed Based Biofuel “Green” the World? Major Universities and Even the U.S. Air Force Seem to Think So 5Varian Medical Systems Groundbreaking on Facility Expansion Triggers Influx of New Jobs to Salt Lake 2Varian Medical Systems Groundbreaking on Facility Expansion Triggers Influx of New Jobs to Salt Lake 3Global Biodegradable Packaging Materials Market 2014-2018 2Global Biodegradable Packaging Materials Market 2014-2018 3Global Biodegradable Packaging Materials Market 2014-2018 4Global Biodegradable Packaging Materials Market 2014-2018 5Global Biodegradable Packaging Materials Market 2014-2018 6Global Biodegradable Packaging Materials Market 2014-2018 7
... Verenium,Corporation (Nasdaq: VRNM ), a leading developer ... development of high-performance specialty,enzymes, announced today that John ... Financial Officer, will present at the upcoming,Piper Jaffray ... to begin at 10:00 a.m. ET on Wednesday, ...
... and Reduce the ... Conn., Feb. 13 VION,PHARMACEUTICALS, INC. (Nasdaq: VION ) ... Omni Hotel in New Haven, Connecticut today at,10:00 Eastern Time., ... the,Company,s Restated Certificate of Incorporation to:, -- effect ...
... Company Posts Fourth Quarter EPS of $0.37, Up 16% -, - For ... Up 41%; Total Revenues and Product ... Income Growth in Four Years, ... $1.72 -, SAN DIEGO, Feb. 13 Gen-Probe Incorporated,(Nasdaq: GPRO ...
Cached Biology Technology:Verenium Corporation to Present at Piper Jaffray Clean Technology & Renewables Conference 2Verenium Corporation to Present at Piper Jaffray Clean Technology & Renewables Conference 3Vion Pharmaceuticals Holds Special Meeting of Stockholders 2Vion Pharmaceuticals Holds Special Meeting of Stockholders 3Gen-Probe Reports Strong Financial Results for Fourth Quarter and Full Year 2007 2Gen-Probe Reports Strong Financial Results for Fourth Quarter and Full Year 2007 3Gen-Probe Reports Strong Financial Results for Fourth Quarter and Full Year 2007 4Gen-Probe Reports Strong Financial Results for Fourth Quarter and Full Year 2007 5Gen-Probe Reports Strong Financial Results for Fourth Quarter and Full Year 2007 6Gen-Probe Reports Strong Financial Results for Fourth Quarter and Full Year 2007 7Gen-Probe Reports Strong Financial Results for Fourth Quarter and Full Year 2007 8Gen-Probe Reports Strong Financial Results for Fourth Quarter and Full Year 2007 9Gen-Probe Reports Strong Financial Results for Fourth Quarter and Full Year 2007 10Gen-Probe Reports Strong Financial Results for Fourth Quarter and Full Year 2007 11Gen-Probe Reports Strong Financial Results for Fourth Quarter and Full Year 2007 12Gen-Probe Reports Strong Financial Results for Fourth Quarter and Full Year 2007 13Gen-Probe Reports Strong Financial Results for Fourth Quarter and Full Year 2007 14Gen-Probe Reports Strong Financial Results for Fourth Quarter and Full Year 2007 15Gen-Probe Reports Strong Financial Results for Fourth Quarter and Full Year 2007 16
(Date:8/27/2014)... when it only requires nerve cells to rearrange existing ... to generate new patterns, a study of monkeys has ... through recordings of electrical activity of brain cell networks. ... of Health. , "We looked into the brain and ... outside the box," said Aaron Batista, Ph.D., an assistant ...
(Date:8/27/2014)... neural circuits in the brain of mice, scientists ... The research, led by Howard Hughes Medical Institute ... Technology (MIT), reveals that the connections between the ... about an experience and the part of the ... experience are malleable. , Altering those connections ...
(Date:8/27/2014)... 2014 University of Utah biologist agan Sekercioglu, who ... won that nation,s highest science prize, which is similar ... is among five researchers picked for 2014 the top ... of Turkey. Three researchers won the Science Award and ... which is equivalent to the Science Award but for ...
Breaking Biology News(10 mins):Scientists plug into a learning brain 2Scientists plug into a learning brain 3Researchers change the emotional association of memories 2Researchers change the emotional association of memories 3Researchers change the emotional association of memories 4University of Utah biologist wins Turkey's top science prize 2
... has only been in Spain for a short time. Far away ... north of Europe where it has already crossed the Alps. Amongst ... of fruit is suitable for it to lay its eggs. This ... more European countries. "Out of the 3,000 known species of ...
... YORK (March 16, 2012)A rapid increase in shipping ... a significant increase in risk to the region,s marine ... for food security and cultural identity, according to an ... convened at a recent workshop. , The workshopwhich ...
... Office of Naval Research (ONR) will bring its technologically ... the 2012 Pacific Operational Science & Technology (S&T) Conference ... a key strategic area for the Navy and Marine ... research. "Gathering worldwide leaders in S&T at this event ...
Cached Biology News:An invasive Asian fly is taking over European fruit 2Increase in Arctic shipping poses risk to marine mammals 2Increase in Arctic shipping poses risk to marine mammals 3Increase in Arctic shipping poses risk to marine mammals 4ONR outreach focuses on Pacific total force 2
... Polyoxyethylene Lauryl Ether ... 0.02% Kathon Preservative. Surfactant. ... in immunohistochemistry is 1 ... 35 solution added to ...
Request Info...
PGC-1 (H-300)...
Mouse VEGF R1/Flt-1 Allophycocyanin MAb (Clone 141522) Keywords: Receptor Tyrosine Kinase, RTK, VEGFR1, VEGF Receptor 1 Protein Family: Receptor Tyrosine Kinases, VEGF/PDGF Family...
Biology Products: